ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,861 to 4,880 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
ABCWY Group vs ACWY Group: Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)96 of 626

93 of 621

0.4 points

-3.6 to 4.3

1,247NCT04707391

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

ABCWY Group vs ACWY Group: deaths from any cause1 of 626

1 of 621

-0.0 points

-0.8 to 0.8

1,247NCT04707391

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

ABCWY Group vs ACWY Group: serious adverse events18 of 626

7 of 621

1.7 points

0.2 to 3.5

1,247NCT04707391

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Sita/Met FDC vs Metformin: serious adverse events28 of 625

38 of 621

-1.6 points

-4.2 to 0.9

1,246NCT00482729

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

Resources for Services RS vs Community Engagement and Planning CEP: deaths from any cause4 of 606

4 of 640

0.0 points

-1.0 to 1.1

1,246NCT01699789

Community Partners in Care is a Research Project Funded by the National Institutes of Health

qHPV Vaccine in Base Study vs qHPV Vaccine in Extension Study: Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up0 of 821

1 of 424

-0.2 points

-1.3 to 0.3

1,245NCT00092547

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Cervarix Group vs Havrix Group: serious adverse events33 of 626

5 of 619

4.5 points

2.6 to 6.6

1,245NCT00316706

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Without Concomitant Drugs vs With Concomitant Drugs: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.3 of 360

15 of 885

-0.9 points

-2.1 to 0.9

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Male vs Female: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.7 of 458

11 of 787

0.1 points

-1.2 to 1.8

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Without Hypertension vs With Hypertension: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.0 of 8

18 of 1,237

-1.5 points

-2.3 to 31.0

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Without Hypercholesterolemia vs With Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.0 of 18

18 of 1,227

-1.5 points

-2.3 to 16.1

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Without Complications vs With Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.5 of 568

13 of 677

-1.0 points

-2.5 to 0.4

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

<65 Years vs >=65 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.5 of 377

13 of 868

-0.2 points

-1.5 to 1.7

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Without Angina Pectoris vs With Angina Pectoris: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.18 of 1,062

0 of 183

1.7 points

-0.5 to 2.7

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Without Familial Hypercholesterolemia vs With Familial Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.18 of 1,231

0 of 14

1.5 points

-20.1 to 2.3

1,245NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Ramucirumab and Docetaxel vs Placebo and Docetaxel: serious adverse events284 of 627

281 of 618

-0.2 points

-5.7 to 5.3

1,245NCT01168973

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Standard Care + Nicotine Replacement Therapy (NRT) vs Standard Care: deaths from any cause1 of 593

3 of 652

-0.3 points

-1.2 to 0.5

1,245NCT02096029

Tobacco Intervention in Primary Care Treatment Opportunities for Providers

Standard Care + Nicotine Replacement Therapy (NRT) vs Standard Care: serious adverse events9 of 593

20 of 652

-1.5 points

-3.3 to 0.2

1,245NCT02096029

Tobacco Intervention in Primary Care Treatment Opportunities for Providers

BE1116 vs Placebo: serious adverse events203 of 618

168 of 627

6.1 points

1.0 to 11.1

1,245NCT05568888

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Palbociclib vs Placebo: deaths from any cause63 of 633

67 of 611

-1.0 points

-4.5 to 2.4

1,244NCT01864746

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=244"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=244

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04707391-4cf64514",
        "title": "ABCWY Group vs ACWY Group: Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)",
        "summary": "96 of 626 against 93 of 621; risk difference 0.4 points, 95% interval -3.6 to 4.3; NCT04707391, Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine",
        "record": "/library/comparisons/NCT04707391-4cf64514",
        "nct_id": "NCT04707391",
        "kind": "outcome",
        "participants": 1247,
        "risk_difference": {
          "value": 0.0035961784815792264,
          "lower": -0.036334236346420745,
          "upper": 0.043488475203239424
        },
        "group_1": "96 of 626",
        "group_2": "93 of 621",
        "difference": "0.4 points",
        "interval": "-3.6 to 4.3",
        "trial_title": "Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine"
      },
      {
        "id": "NCT04707391-deaths",
        "title": "ABCWY Group vs ACWY Group: deaths from any cause",
        "summary": "1 of 626 against 1 of 621; risk difference -0.0 points, 95% interval -0.8 to 0.8; NCT04707391, Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine",
        "record": "/library/comparisons/NCT04707391-deaths",
        "nct_id": "NCT04707391",
        "kind": "deaths",
        "participants": 1247,
        "risk_difference": {
          "value": -0.000012861868675176141,
          "lower": -0.007582118993223607,
          "upper": 0.00750008163523229
        },
        "group_1": "1 of 626",
        "group_2": "1 of 621",
        "difference": "-0.0 points",
        "interval": "-0.8 to 0.8",
        "trial_title": "Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=245",
  "request_id": "snqCn6_c-wdgWH4i"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?